Pular para o conteúdo principal
Ranking Invest

CERS - Cerus Corporation

Segmento: HealthcareCerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Análise Ranking Invest

Valuation estimado
-$ 18.53 Mi
Valor de Mercado
$ 501.80 Mi
Desconto (AV)-2807.5%
IVR
-0.04A companhia vale -0,04 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.18O valuation alternativo equivale a -18% do valor de mercado da companhia.
MLL
-0.18O lucro líquido dos controladores em 16 trimestres equivale a -18% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 69.33 Mi

Dívida Líquida

-$ 17.98 Mi

L4T

-$ 6.78 Mi

MM4T

-2.04%

Indicadores Básicos

ROE

-9.78%

Índices de Previsibilidade

Receita Líquida

F0.41

Lucro

D0.61

Margem

D1.07

Índices de Tendência

Receita Líquida

D-2.47

Lucro

A8.84

Margem

A8.98

Índices de Endividamento

DIV/PAT

-0.26

DIV/L4T

2.65

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.